Calidi Biotherapeutics, Inc.

NYSE American CLDI

Calidi Biotherapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Calidi Biotherapeutics, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
SV Wall Street
NYSE American: CLDI

Calidi Biotherapeutics, Inc.

CEO Mr. Allan J. Camaisa
IPO Date Nov. 1, 2021
Location United States
Headquarters 4475 Executive Drive
Employees 41
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

StockViz Staff

February 6, 2025

Any question? Send us an email